Synergistic inhibitory effects of 5-aza-2'-deoxycytidine and cisplatin on urothelial carcinoma growth via suppression of TGFBI-MAPK signaling pathways

被引:3
|
作者
Shang, Donghao [1 ]
Li, Gang [2 ]
Zhang, Caixing [1 ]
Liu, Yuting [3 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing 100050, Peoples R China
[2] China Med Univ, Liaoning Canc Hosp & Inst, Dept Urol, Canc Hosp, Shenyang 110042, Liaoning, Peoples R China
[3] Capital Med Univ, Dept Pathol, Beijing 100069, Peoples R China
关键词
urothelial carcinoma; DAC; CDDP; TGFBI; MAPK; 5-AZA-2'-DEOXYCYTIDINE ENHANCES SUSCEPTIBILITY; TRANSITIONAL-CELL CARCINOMA; DNA METHYLATION; PROMOTER METHYLATION; BREAST-CANCER; BLADDER; AGENT; DECITABINE; EXPRESSION; PACLITAXEL;
D O I
10.1139/bcb-2021-0277
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study aimed to reveal the gene transcriptional alterations, possible molecular mechanisms, and pathways and T24, were used in the present study. A cDNA microarray was performed to identify critical genes involved in the synergistic mechanism of both agents against UC cells. The results showed that several key regulatory genes, such as interleukin 24 (IL24), fibroblast growth factor 1 (FGF1), and transforming growth factor beta induced (TGFBI), may play critical roles in the synergy of DAC and CDDP in UC. Pathway enrichment suggested that many carcinogenesis-related pathways, such as the ECM-receptor interaction and MAPK signaling pathways, may participate in the synergy of both agents. Our results suggest that TGF-I31 stimulates the phosphorylation of ERK1/2 and p38 by increasing TGFBI expression, and that the TGFBI-MAPK signaling pathway plays an important role in the synergy of DAC and CDDP against UC. Therefore, we revealed the synergistic mechanism of DAC and CDDP in UC. Several key regulatory genes play critical roles in the synergy of combined treatment, and the TGFBI-MAPK signaling pathway may be an important potential target of these two agents.
引用
收藏
页码:115 / 124
页数:10
相关论文
共 48 条
  • [21] 5-Aza-2′-deoxycytidine induces retinoic acid receptor β2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells
    Yang, QF
    Shan, L
    Yoshimura, G
    Nakamura, M
    Nakamura, Y
    Suzuma, T
    Umemura, T
    Mori, I
    Sakurai, T
    Kakuda, K
    ANTICANCER RESEARCH, 2002, 22 (05) : 2753 - 2756
  • [22] 5-AZA-2'-DEOXYCYTIDINE (ADC) - TEMPORAL KINETICS AND SCHEDULE DEPENDENCE OF GROWTH-INHIBITION (GI) EFFECTS ON SQUAMOUS-CELL CARCINOMA (SCC) INVITRO
    LEYVA, A
    BOEIJE, L
    OBRIEN, A
    PINEDO, H
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 329 - 329
  • [23] 5-aza-2′-deoxycytidine promotes migration of acute monocytic leukemia cells via activation of CCL2-CCR2-ERK signaling pathway
    Xiao, Xia
    Xu, Qian
    Sun, Yan
    Lu, Ziwei
    Li, Rui
    Wang, Xinxin
    Jiang, Xin
    Zhang, Guirong
    Xiao, Yechen
    MOLECULAR MEDICINE REPORTS, 2017, 16 (02) : 1417 - 1424
  • [24] Synergistic effects of MBD2 knock down and 5-aza-2\#8217;-deoxycytidine (5AzadC) on inhibiting breast cancer growth and invasiveness: Blocking global hypomethylation and prometastatic effects of 5AzadC
    Chik, Flora
    Szyf, Moshe
    CANCER RESEARCH, 2009, 69
  • [25] Retinoic acid receptor β2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2′-deoxycytidine treatment
    F. Y. Miasaki
    A. Vivaldi
    R. Ciampi
    L. Agate
    P. Collecchi
    A. Capodanno
    A. Pinchera
    R. Elisei
    Journal of Endocrinological Investigation, 2008, 31 : 724 - 730
  • [26] Retinoic acid receptor β2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2′-deoxycytidine treatment
    Miasaki, F. Y.
    Vivaldi, A.
    Ciampi, R.
    Agate, L.
    Collecchi, P.
    Capodanno, A.
    Pinchera, A.
    Elisei, R.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (08) : 724 - 730
  • [27] 5-aza-2′-deoxycytidine and trichostathin A enhanced growth inhibitory effect of all trans retinoic acid by the restoration of retinoic acid receptor β expression in head and neck squamous carcinoma cells
    Whang, YM
    Choi, EJ
    Jung, HY
    Han, SGL
    Koh, IS
    Kim, JS
    Yoo, YD
    Kim, YH
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S85 - S86
  • [28] Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration
    Xi, Wenjin
    Chen, Xu
    Sun, Jinbo
    Wang, Wei
    Huo, Yi
    Zheng, Guoxu
    Wu, Jieheng
    Li, Yufang
    Yang, Angang
    Wang, Tao
    MEDICAL SCIENCE MONITOR, 2018, 24 : 1034 - 1043
  • [29] Restoration of expression of transforming growth factor-β type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2′-deoxycytidine
    Zhang, Q
    Rubenstein, JN
    Liu, VC
    Park, I
    Jang, T
    Lee, C
    LIFE SCIENCES, 2005, 76 (10) : 1159 - 1166
  • [30] The Effects of 5-Aza-2′-Deoxycytidine and Valproic Acid on Apoptosis Induction and Cell Growth Inhibition in Colon Cancer HT 29 Cell Line
    Sanaei, Masumeh
    Kavoosi, Fraidoon
    Sahraeian, Hamed
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2021, 12 (01)